Osmind vs Idexx Laboratories

Side-by-side comparison of AI visibility scores, market position, and capabilities

Idexx Laboratories leads in AI visibility (94 vs 62)
Osmind logo

Osmind

ChallengerHealthcare

General

SF YC W20 psychiatric EHR for ketamine/psychedelic/TMS treatment practices; $55.2M total ($40M DFJ/General Catalyst/Tiger Series B May 2022) competing with Valant for emerging mental health treatment specialty EHR.

AI VisibilityBeta
Overall Score
B62
Category Rank
#145 of 1158
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
65
Perplexity
66
Gemini
59

About

Osmind is a San Francisco-based psychiatry and mental health EHR (electronic health record) platform — backed by Y Combinator (W20) with $55.2 million in total funding including a $40 million Series B in May 2022 led by DFJ Growth with General Catalyst, Future Ventures, Tiger Global, Susa Ventures, Lachy Groom, and Pear VC — providing psychiatric practices with research-grade EHR technology specialized for emerging mental health treatments including ketamine therapy, psychedelic-assisted psychotherapy (psilocybin, MDMA), transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT). Founded in 2020, Osmind captures clinical data during novel psychiatric interventions in structured formats that enable both optimized patient care workflows and real-world evidence research — serving the growing segment of psychiatric practices offering treatment-resistant depression interventions.

Full profile
Idexx Laboratories logo

Idexx Laboratories

LeaderHealthcare Tech

Enterprise

Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.

AI VisibilityBeta
Overall Score
A94
Category Rank
#19 of 290
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
92
Gemini
88

About

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.

Full profile

AI Visibility Head-to-Head

62
Overall Score
94
#145
Category Rank
#19
80
AI Consensus
71
stable
Trend
stable
65
ChatGPT
99
66
Perplexity
92
59
Gemini
88
62
Claude
94
59
Grok
99

Key Details

Category
General
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.